Answers are grounded in this paper and cite their sources.
This assay demonstrates zasocitinib preserves IL-10 signalling in immune-mediated inflammatory diseases, indicating potential therapeutic benefits.
Background Zasocitinib (TAK-279) is an investigational, oral, allosteric, highly selective and potent tyrosine kinase 2 (TYK2) inhibitor in clinical development for immune-mediated inflammatory diseases (IMIDs), including Inflammatory Bowel Disease (IBD). TYK2 mediates signalling downstream of IL-12, IL-23 and type I IFN, which drive immune responses that perpetuate intestinal inflammation. IL-10 is a key anti-inflammatory cytokine that signals via the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway to limit pro-inflammatory cytokine production and maintain mucosal immune tolerance. Loss of IL-10 or IL-10 receptor signalling leads to very early-onset IBD, highlighting its essential role in preserving gut homeostasis and supporting regulatory T cell activity. This study assessed the effect of zasocitinib, deucravacitinib (TYK2 inhibitor) and upadacitinib (JAK1 inhibitor) treatment on IL-10 signalling. Methods Human whole blood from healthy volunteers (n = 12) was incubated with increasing concentrations (0.51 nM–10 μM) of zasocitinib, deucravacitinib or upadacitinib, and stimulated with IL-10 (10 ng/mL). IL-10 signalling was assessed by phosphorylated STAT3 (pSTAT3) relative to non-cytokine treated pSTAT3 signal via flow cytometry, and half maximal inhibitory concentrations (IC50) were calculated. IL-10-dependent (10 ng/mL) suppression of lipopolysaccharide (10 μg/mL)-induced IL-1β, IL-6 and TNFα was measured in human whole blood following treatment with 10 μM of zasocitinib (n = 11), deucravacitinib (n = 11) or upadacitinib (n = 7). RNA sequencing evaluated IL-10-responsive gene expression in whole blood from healthy volunteers (n = 4) treated with up to 10 μM of zasocitinib, deucravacitinib or upadacitinib. Results In the IL-10-pSTAT3 assay, an IC50 value could not be determined for zasocitinib, suggesting preservation of IL-10 signalling. IC50 values for deucravacitinib and upadacitinib were 331 (95% CI 301–365) nM and 307 (263–362) nM, respectively. IL-10-mediated suppression of IL-1β, IL-6 and TNFα was preserved with zasocitinib; deucravacitinib and upadacitinib significantly attenuated IL-10-mediated cytokine suppression (Figure 1). Following IL-10 stimulation, 28 out of the top 30 upregulated genes continued to be expressed after treatment with zasocitinib versus 6/30 and 12/30 with deucravacitinib and upadacitinib, respectively. Conclusion Zasocitinib preserved IL-10 signalling and suppression of pro-inflammatory cytokines. Given the immunosuppressive role of IL-10 in IBD, these observations support the ongoing investigation of zasocitinib as a potential therapeutic for patients. Ongoing clinical trials will further evaluate efficacy and safety of zasocitinib in patients with IMIDs, including IBD. Conflict of interest: Dr. Orlandi, Chiara: Employee of Takeda Development Center Americas, Inc. Lin, Kuan-Yin: Employee of Takeda Development Center Americas, Inc Kumar, Sachin: Employee of Takeda Development Center Americas, Inc Sherlock, Jonathan: Employee of Takeda Development Center Americas, Inc Wilson, Elizabeth: Employee of Takeda Development Center Americas, Inc Petrakis, Ioannis: Employee of Takeda Development Center Americas, Inc Salas, Azucena: Received research grants from AbbVie, Pfizer and Takeda.
No takes yet. Share an insight, caveat, or question.
Orlandi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: